Targeting critical needs
At Masinova, our therapeutic focus is on addressing significant unmet needs in HIV infection, cancers, and autoimmune diseases. We employ a rigorous, Quality-by-Design approach to accelerate the development of innovative therapies from preclinical stages to Phase I trials. We invite potential investors and strategic partners to join us in advancing these programs.
Our therapeutic areas
Masinova is dedicated to developing targeted therapies for critical diseases. Our commitment to Quality-by-Design ensures that our programs are designed for reproducibility, safety, and efficient translation. We are actively seeking partnerships and investments to further our research and development efforts.
HIV infection
We are developing innovative therapies to combat HIV infection, focusing on novel approaches to improve patient outcomes.
Cancers
Our oncology program targets various cancers with high-unmet needs, employing a Quality-by-Design strategy to accelerate development.
Autoimmune diseases
We are pioneering therapies for autoimmune diseases, aiming to modulate the immune response and improve patient quality of life.
Partner with masinova
We invite investors, big pharma, and biotech R&D leaders to contact us for partnership and investment opportunities. Discuss how our rigor-led therapeutic R&D can benefit your portfolio. Confidential program overviews are available under NDA.
Quality-by-design approach
Our Quality-by-Design principles ensure reproducibility, safety, and efficient translation from discovery to preclinical milestones. This rigorous approach sets us apart and accelerates our therapeutic development process.
Investment & partnership
Masinova is actively seeking investors and strategic partners to advance our HIV, cancer, and autoimmune therapy programs. Contact us to learn more about partnering and investment opportunities.
